Home » Stocks » ARTH

Arch Therapeutics, Inc. (ARTH)

Stock Price: $0.1850 USD -0.0050 (-2.63%)
Updated Jan 26, 2021 10:14 AM EST - Market open
Market Cap 35.08M
Revenue (ttm) n/a
Net Income (ttm) -4.69M
Shares Out 188.05M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE 10.75
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $0.1850
Previous Close $0.1900
Change ($) -0.0050
Change (%) -2.63%
Day's Open 0.1900
Day's Range 0.1750 - 0.1900
Day's Volume 16,550
52-Week Range 0.1251 - 0.26

News

Hide News
  • All
  • Videos
  • Press Releases
GlobeNewsWire - 3 weeks ago

FRAMINGHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, ann...

GlobeNewsWire - 3 weeks ago

Partnership provides US government facilities access and product distribution support Partnership provides US government facilities access and product distribution support

GlobeNewsWire - 1 month ago

FRAMINGHAM, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, ann...

GlobeNewsWire - 2 months ago

Financing with long-term shareholders provides flexibility during product roll-out Financing with long-term shareholders provides flexibility during product roll-out

GlobeNewsWire - 2 months ago

Clinical case reports and animal studies that were presented support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds Clinical case reports a...

GlobeNewsWire - 3 months ago

Live moderated video webcast discussion of AC5 Advanced Wound System among management and Key Opinion Leaders on Wednesday, October 28th at 12:00 PM ET Live moderated video webcast discussion ...

GlobeNewsWire - 3 months ago

A series of clinical case reports and animal studies support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds A series of clinical case repor...

Seeking Alpha - 4 months ago

Arch Therapeutics has FDA and EMA approval for AC5.

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - September 22, 2020) -  Arch Therapeutics, Inc. (OTCQB: ARTH) has cleared significant hurdles to commercialize its AC5 Advanced Wound System and AC5 Topica...

Seeking Alpha - 4 months ago

Arch Therapeutics Reports First Pressure Ulcer Case Results

GlobeNewsWire - 4 months ago

FRAMINGHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devi...

GlobeNewsWire - 5 months ago

FRAMINGHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devic...

GlobeNewsWire - 5 months ago

Emerging technology presentation demonstrates use of AC5-GTM in submucosal lifting and management of gastrointestinal bleeding during porcine endoscopic procedures. Emerging technology present...

GlobeNewsWire - 5 months ago

Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection Emerging Technology vid...

GlobeNewsWire - 7 months ago

Live video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A session Live video moderated discussion with Dr. T...

GlobeNewsWire - 7 months ago

Financing with long-term shareholders provides flexibility during product roll-out Financing with long-term shareholders provides flexibility during product roll-out

Zacks Investment Research - 7 months ago

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

Other stocks mentioned: AAXN, BYND, CENX, CHWY, DXCM, ORN, PCH, SRPT, TNAV, TWLO
Seeking Alpha - 1 year ago

Only funds with coverage >100% are considered.

About ARTH

Arch Therapeutics, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was fo... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
Dr. Terrence W. Norchi
Employees
7
Stock Exchange
OTCMKTS
Ticker Symbol
ARTH
Full Company Profile

Financial Performance

Financial Statements